Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2020

View Archived Issues

Evaluating the clinical significance of KIAA1199 expression in locally advanced gastric cancer

S166 phosphorylation is essential for cell death and inflammation in RIPK1-dependent diseases

Study of de novo missense EIF2K2 variants as responsible for neurological disorders

Insulin cuts both ways in vasculature

Transcriptomic insights into Parkinson's disease

FDA approves IND application for CAN-04

Successful completion of phase II study of SPI-1005 in bipolar disorder

Phase III trial of Solosec for trichomoniasis meets primary endpoint

First COVID-19 patient enrolled in ongoing phase III study of AR-301

Eli Lilly and Company patents new KRAS G12C inhibitors

Viriom initiates phase II study of long-acting injectable VM-1500A

Intarcia Therapeutics discloses new amylin analogues

New SSTR5 agonists presented by Heptares Therapeutics

CytoDyn requests compassionate use of leronlimab for COVID-19

Takeda Pharmaceutical synthesizes mTOR inhibitors

Shanghai Ennova Biopharmaceutical identifies new TRK inhibitors

Allakos reports interim data from open-label extension study of antolimab

GDC-9545, a third-generation ER-alpha ligand with improved potency

Phase III data for HL-301 in acute bronchitis

Novel ADPRHL2 gene mutation linked to newly identified neurological syndrome

First preclinical results presented for XmAb bispecific antibody AMG-509

Sphingolipid may be new schizophrenia drug target

Promising topline data reported from pivotal trial of Libtayo in advanced BCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...